We provide you with 20 years of free, institutional-grade data for CLRB stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of CLRB. Explore the full financial landscape of CLRB stock.
Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$0
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|
The information provided in this report about CLRB stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Cellectar Biosciences, Inc(NASDAQ:CLRB) 
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131, which is in Phase II clinical study in patients with relapsed or refr...
Website: http://www.cellectar.com
Founded: 1996
Full Time Employees: 8
Sector: Healthcare
Industry: Biotechnology